Vifor Fresenius Medical Care Renal Pharma (Vfmcrp) And Cara Therapeutics, Inc. Announced That They Have Received Approval For Kapruvia From The Swiss Agency For Therapeutic Products (Swissmedic). Kapruvia Will Be The First Therapy Available For The Treatment Of Moderate-To-Severe Pruritus Associated With Chronic Kidney Disease In Adult Haemodialysis Patients. Swissmedic Approval For Kapruvia Follows Approvals By The Us Food And Drug Administration, By The European Medicines Agency, By The Uk Medicines And Healthcare Products Regulatory Agency, As Well As By Health Canada.
